JANX Stock Overview
A clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Janux Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$50.31 |
52 Week High | US$65.60 |
52 Week Low | US$7.79 |
Beta | 3.52 |
11 Month Change | -5.80% |
3 Month Change | 8.45% |
1 Year Change | 445.07% |
33 Year Change | 184.88% |
5 Year Change | n/a |
Change since IPO | 100.04% |
Recent News & Updates
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business
Oct 01Janux Therapeutics: Buoyed By Buyout Speculation
Sep 01Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Jul 01Recent updates
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business
Oct 01Janux Therapeutics: Buoyed By Buyout Speculation
Sep 01Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Jul 01Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
Apr 11Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
Feb 27Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth
Feb 24Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?
Dec 29Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely
Jul 20A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)
May 23Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Feb 09We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth
Oct 19Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M
Aug 09We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth
Jun 05Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Feb 19Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Nov 03Shareholder Returns
JANX | US Biotechs | US Market | |
---|---|---|---|
7D | 3.2% | 2.5% | 2.2% |
1Y | 445.1% | 16.1% | 31.6% |
Return vs Industry: JANX exceeded the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: JANX exceeded the US Market which returned 31.7% over the past year.
Price Volatility
JANX volatility | |
---|---|
JANX Average Weekly Movement | 7.3% |
Biotechs Industry Average Movement | 9.8% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: JANX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: JANX's weekly volatility has decreased from 34% to 7% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 76 | David Campbell | www.januxrx.com |
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company’s clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products.
Janux Therapeutics, Inc. Fundamentals Summary
JANX fundamental statistics | |
---|---|
Market cap | US$2.64b |
Earnings (TTM) | -US$60.54m |
Revenue (TTM) | US$13.05m |
202.3x
P/S Ratio-43.6x
P/E RatioIs JANX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
JANX income statement (TTM) | |
---|---|
Revenue | US$13.05m |
Cost of Revenue | US$59.82m |
Gross Profit | -US$46.77m |
Other Expenses | US$13.76m |
Earnings | -US$60.54m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.15 |
Gross Margin | -358.45% |
Net Profit Margin | -463.91% |
Debt/Equity Ratio | 0% |
How did JANX perform over the long term?
See historical performance and comparison